Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind crossover study of olodaterol dose comparison in moderate to severe persistent asthma
2008-006625-14Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of olodaterol in asthma and persistent asthma (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: FEV1 AUC0-24h response after three weeks of treatment. Started Dec 2010; status: completed.
02
Drugs
olodaterol
03
Conditions
asthmapersistent asthma
Beyond the preview
Go deeper on 2008-006625-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006625-14.